Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors
John Porter(UCB Pharma (United Kingdom)), Colin Stubberfield(UCB Pharma (United Kingdom)), James M. A. Turner(The Francis Crick Institute), Brian Hutchinson(Joint Global Change Research Institute), Ben de Candole(UCB Pharma (United Kingdom)), Jeremy Davis(UCB Pharma (United Kingdom)), Chloe Edwards(UCB Pharma (United Kingdom)), Ian Whitcombe(UCB Pharma (United Kingdom)), Clare Watkins(UCB Pharma (United Kingdom)), Graham Trevitt(UCB Pharma (United Kingdom)), Andrew Payne(Provo College), Daniel Ford(UCB Pharma (United Kingdom))
Cited by 126
Related Papers
Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions
|The American Journal of Surgical Pathology|2003|611
PRCC-TFE3 Renal Carcinomas
|The American Journal of Surgical Pathology|2002|362
Renal Carcinomas With the t(6;11)(p21;q12)
|The American Journal of Surgical Pathology|2005|291
Translocation Carcinomas of the Kidney After Chemotherapy in Childhood
|Journal of Clinical Oncology|2006|275
Deep Learning for Unsupervised Insider Threat Detection in Structured\n Cybersecurity Data Streams
|arXiv (Cornell University)|2017|186